BR112019020211A2 - composições de niraparib - Google Patents
composições de niraparib Download PDFInfo
- Publication number
- BR112019020211A2 BR112019020211A2 BR112019020211-0A BR112019020211A BR112019020211A2 BR 112019020211 A2 BR112019020211 A2 BR 112019020211A2 BR 112019020211 A BR112019020211 A BR 112019020211A BR 112019020211 A2 BR112019020211 A2 BR 112019020211A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- fact
- piperidin
- phenyl
- indazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477411P | 2017-03-27 | 2017-03-27 | |
| US62/477.411 | 2017-03-27 | ||
| PCT/US2018/024603 WO2018183354A1 (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019020211A2 true BR112019020211A2 (pt) | 2020-04-22 |
Family
ID=63676949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019020211-0A BR112019020211A2 (pt) | 2017-03-27 | 2018-03-27 | composições de niraparib |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11091459B2 (enExample) |
| EP (1) | EP3600314A1 (enExample) |
| JP (1) | JP2020512350A (enExample) |
| KR (1) | KR20200014736A (enExample) |
| CN (1) | CN110944638A (enExample) |
| AU (2) | AU2018246214B2 (enExample) |
| BR (1) | BR112019020211A2 (enExample) |
| CA (1) | CA3058375C (enExample) |
| EA (1) | EA201992177A1 (enExample) |
| IL (1) | IL269630A (enExample) |
| MX (1) | MX2019011496A (enExample) |
| SG (1) | SG11201909011PA (enExample) |
| TW (1) | TWI761476B (enExample) |
| WO (1) | WO2018183354A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3478286T (pt) | 2016-06-29 | 2024-01-31 | Tesaro Inc | Métodos de tratamento do cancro do ovário |
| WO2018183354A1 (en) | 2017-03-27 | 2018-10-04 | Tesaro, Inc. | Niraparib compositions |
| AU2018258274C1 (en) | 2017-04-24 | 2021-12-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| EP3687505A1 (en) | 2017-09-26 | 2020-08-05 | Tesaro Inc. | Niraparib formulations |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| EP3749352A1 (en) | 2018-02-05 | 2020-12-16 | Tesaro Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| US12297184B2 (en) | 2018-10-03 | 2025-05-13 | Tesaro, Inc. | Niraparib salts |
| WO2020072860A1 (en) * | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
| CA3087392A1 (en) | 2019-07-16 | 2021-01-16 | Apotex Inc. | Crystalline forms of niraparib tosylate |
| MX2022014003A (es) | 2020-05-08 | 2022-11-30 | Janssen Pharmaceutica Nv | Tratamientos del cancer de prostata con combinaciones de acetato de abiraterona y niraparib. |
| US20240325369A1 (en) | 2021-07-19 | 2024-10-03 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
| WO2024238587A1 (en) | 2023-05-17 | 2024-11-21 | Tesaro, Inc. | Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4611441B2 (ja) | 2006-04-03 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体 |
| GB0606663D0 (en) | 2006-04-03 | 2006-05-10 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2008043024A2 (en) | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
| RS51780B (sr) * | 2007-01-10 | 2011-12-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
| WO2009050469A1 (en) * | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one |
| NZ586675A (en) * | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| AU2010289746B2 (en) * | 2009-08-26 | 2016-07-07 | Cephalon, Inc. | Novel forms of a multicyclic compound |
| CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| WO2014088983A1 (en) | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| WO2014088984A1 (en) | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| US9191894B2 (en) * | 2013-07-23 | 2015-11-17 | Disney Enterprises, Inc. | Power saving for multi-hop communications |
| WO2015103526A1 (en) | 2014-01-05 | 2015-07-09 | Washington University | Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor |
| US9718841B2 (en) | 2014-04-22 | 2017-08-01 | Calitor Sciences, Llc | Bicyclic pyrazolone compounds and methods of use |
| WO2015184145A1 (en) | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| RU2705156C2 (ru) | 2014-08-22 | 2019-11-05 | Кловис Онколоджи, Инк. | Таблетки, содержащие большую дозу рукапариба |
| WO2016094391A1 (en) | 2014-12-08 | 2016-06-16 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| HRP20211511T1 (hr) | 2015-07-02 | 2021-12-24 | Acerta Pharma B.V. | Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida |
| PT3478286T (pt) | 2016-06-29 | 2024-01-31 | Tesaro Inc | Métodos de tratamento do cancro do ovário |
| CN106496187A (zh) * | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106831708A (zh) | 2016-11-22 | 2017-06-13 | 西安泰科迈医药科技股份有限公司 | 一种新型口服抗癌药物Nirapairb的合成方法 |
| CN108201537A (zh) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| CN106854176A (zh) | 2016-12-21 | 2017-06-16 | 南京艾德凯腾生物医药有限责任公司 | 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018183354A1 (en) | 2017-03-27 | 2018-10-04 | Tesaro, Inc. | Niraparib compositions |
| EP3606523A1 (en) | 2017-03-27 | 2020-02-12 | Tesaro, Inc. | Niraparib formulations |
| AU2018258274C1 (en) | 2017-04-24 | 2021-12-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| CN108530425A (zh) | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| EP3687505A1 (en) | 2017-09-26 | 2020-08-05 | Tesaro Inc. | Niraparib formulations |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
| WO2019133697A1 (en) | 2017-12-27 | 2019-07-04 | Tesaro, Inc. | Methods of treating cancer |
| EP3749352A1 (en) | 2018-02-05 | 2020-12-16 | Tesaro Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| US12297184B2 (en) * | 2018-10-03 | 2025-05-13 | Tesaro, Inc. | Niraparib salts |
| CA3087392A1 (en) * | 2019-07-16 | 2021-01-16 | Apotex Inc. | Crystalline forms of niraparib tosylate |
-
2018
- 2018-03-27 WO PCT/US2018/024603 patent/WO2018183354A1/en not_active Ceased
- 2018-03-27 EP EP18774912.2A patent/EP3600314A1/en not_active Withdrawn
- 2018-03-27 MX MX2019011496A patent/MX2019011496A/es unknown
- 2018-03-27 CN CN201880033357.6A patent/CN110944638A/zh active Pending
- 2018-03-27 BR BR112019020211-0A patent/BR112019020211A2/pt not_active Application Discontinuation
- 2018-03-27 SG SG11201909011P patent/SG11201909011PA/en unknown
- 2018-03-27 TW TW107110575A patent/TWI761476B/zh active
- 2018-03-27 KR KR1020197031668A patent/KR20200014736A/ko not_active Ceased
- 2018-03-27 CA CA3058375A patent/CA3058375C/en active Active
- 2018-03-27 JP JP2019553055A patent/JP2020512350A/ja active Pending
- 2018-03-27 AU AU2018246214A patent/AU2018246214B2/en active Active
- 2018-03-27 EA EA201992177A patent/EA201992177A1/ru unknown
-
2019
- 2019-09-25 IL IL26963019A patent/IL269630A/en unknown
- 2019-09-26 US US16/584,401 patent/US11091459B2/en active Active
-
2021
- 2021-06-04 US US17/339,896 patent/US11673877B2/en active Active
- 2021-10-08 AU AU2021245223A patent/AU2021245223A1/en not_active Abandoned
-
2023
- 2023-05-01 US US18/310,238 patent/US20230416223A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021245223A1 (en) | 2021-11-04 |
| JP2020512350A (ja) | 2020-04-23 |
| US20230416223A1 (en) | 2023-12-28 |
| CA3058375A1 (en) | 2018-10-04 |
| EA201992177A1 (ru) | 2020-02-25 |
| TWI761476B (zh) | 2022-04-21 |
| CA3058375C (en) | 2025-05-06 |
| TW201840315A (zh) | 2018-11-16 |
| US20200017462A1 (en) | 2020-01-16 |
| AU2018246214A1 (en) | 2019-11-07 |
| AU2018246214B2 (en) | 2021-07-08 |
| KR20200014736A (ko) | 2020-02-11 |
| IL269630A (en) | 2019-11-28 |
| US20210403448A1 (en) | 2021-12-30 |
| CN110944638A (zh) | 2020-03-31 |
| US11091459B2 (en) | 2021-08-17 |
| SG11201909011PA (en) | 2019-10-30 |
| US11673877B2 (en) | 2023-06-13 |
| WO2018183354A1 (en) | 2018-10-04 |
| EP3600314A1 (en) | 2020-02-05 |
| MX2019011496A (es) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11673877B2 (en) | Niraparib compositions | |
| US20240082231A1 (en) | Niraparib formulations | |
| ES2354971T3 (es) | Uso oftalmológico de roflumilast para el tratamiento de enfermedades de los ojos. | |
| ES2829279T3 (es) | Forma de dosificación oral de ketamina | |
| JP5600747B2 (ja) | 口腔内分散性製剤 | |
| ES2261655T3 (es) | Composicion farmaceutica solida que comprende 4'-ciano-trifluoro-3-(4-fluorofenilsulfonil)-2-hidroxi-2-metilpropiono-m-toluiduro y pvp. | |
| PT2575778T (pt) | Composições farmacêuticas de co-cristais de tramadol e coxibs | |
| KR20190000929A (ko) | 리카르바제핀 아세테이트를 포함하는 경구 투여형 | |
| ES2881883T3 (es) | Composiciones farmacéuticas que comprenden derivado de fenilaminopirimidina | |
| PT1958617E (pt) | Composições farmacêuticas contendo fumarato de quetiapina | |
| JP3639587B2 (ja) | 医薬製剤 | |
| BR112019026029A2 (pt) | Formulações farmacêuticas orais de remogliflozina | |
| US20060034911A1 (en) | New oral immediated release dosage form | |
| JP2025512713A (ja) | 麻酔薬化合物ならびに疼痛症状を処置または予防するためのその製造方法および使用方法 | |
| WO2016012398A1 (en) | Zaltoprofen and muscle relaxant combinations | |
| US20220257611A1 (en) | A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby | |
| EP2976067B1 (en) | Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof | |
| KR101506627B1 (ko) | 아세브로필린 및 친수성 서방기제를 포함하는 서방형 약학 조성물 | |
| ES2692095T3 (es) | Comprimidos de imatinib de dosis alta | |
| KR20240155526A (ko) | 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |